Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03391778 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

StatusEnrolling by Invitation
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Recruiting → Enrolling by Invitation Site details revised at 24 of 24 sitesv32 Show 1 more changeShow less
    • Site details revised at 24 of 24 sites
  2. Lead sponsor: Adaptimmune to USWM CT, LLC Study sites revised (24)v31 Show 1 more changeShow less
    • Study sites revised (24)

    See this version in full on ClinicalTrials.gov ↗

  3. Lead sponsor: GlaxoSmithKline to Adaptimmune Study sites: 29 to 24 · Interventions: GSK adoptive cell therapy (Biological) to ADP adoptive cell therapy (Biological) · Eligibility criteria revised · 1 morev30 Show 4 more changesShow less
    • Study sites: 29 to 24
    • Interventions: GSK adoptive cell therapy (Biological) to ADP adoptive cell therapy (Biological)
    • Eligibility criteria revised
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 45 to 29v29
  5. Site details revised at 4 of 45 sitesv28
Show 26 earlier versionsHide 26 earlier versions
  1. Study sites: 37 to 45v27
  2. Study sites: 38 to 37v26
  3. Study sites: 39 to 38v25
  4. Site details revised at 29 of 39 sitesv24
  5. Study sites: 38 to 39v23
  6. Site contacts updated at 1 of 38 sitesv22
  7. Study sites: 37 to 38v21
  8. Start date: Nov 22, 2017 to Apr 9, 2018 Primary endpoint revised · Study sites: 19 to 37 · Interventions: GSK3377794 (NY-ESO-1ᶜ²⁵⁹ T) (Genetic) to GSK adoptive cell therapy (Biological) · 4 morev20 Show 7 more changesShow less
    • Primary endpoint revised
    • Study sites: 19 to 37
    • Interventions: GSK3377794 (NY-ESO-1ᶜ²⁵⁹ T) (Genetic) to GSK adoptive cell therapy (Biological)
    • Eligibility criteria expanded, about 42 words
    • Secondary endpoints revised (5)
    • Study description shortened, about 95 words
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  9. Enrollment target: 444 to 250 Study sites: 17 to 19v19 Show 1 more changeShow less
    • Study sites: 17 to 19
  10. Study sites: 15 to 17v18
  11. Start date: Sep 28, 2011 to Nov 22, 2017 Study sites: 14 to 15v17 Show 1 more changeShow less
    • Study sites: 14 to 15
  12. Enrollment target: 200 to 444 Study sites: 13 to 14v16 Show 1 more changeShow less
    • Study sites: 13 to 14
  13. Study sites: 12 to 13v15
  14. Study sites: 11 to 12v14
  15. Study sites: 9 to 11v13
  16. Site details revised at 1 of 9 sitesv12
  17. Study sites: 6 to 9 Start date: Nov 22, 2017 to Sep 28, 2011v11 Show 1 more changeShow less
    • Start date: Nov 22, 2017 to Sep 28, 2011
  18. Start date: Apr 9, 2018 to Nov 22, 2017v10
  19. Study sites: 7 to 6v9
  20. Phase: Not specified to Phase 1 Lead sponsor: Adaptimmune to GlaxoSmithKline · Enrollment target: 300 to 200 · Primary and study completion dates: May 2047 to Apr 1, 2032 · 8 morev8 Show 11 more changesShow less
    • Lead sponsor: Adaptimmune to GlaxoSmithKline
    • Enrollment target: 300 to 200
    • Primary and study completion dates: May 2047 to Apr 1, 2032
    • Primary endpoint revised
    • Trial status: Enrolling by Invitation to Recruiting
    • Interventions: NY-ESO-1ᶜ²⁵⁹T (Genetic) to GSK3377794 (NY-ESO-1ᶜ²⁵⁹ T) (Genetic)
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: 4 to 5
    • Study description shortened, about 10 words
    • Study sites revised (7)
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  21. Study sites: 6 to 7v7
  22. Study sites: 5 to 6v6
  23. Study sites: 4 to 5v5
  24. Study sites: 3 to 4v4
  25. Study sites: 2 to 3 Start date changed from estimate of Apr 2018 to Apr 9, 2018v3 Show 1 more changeShow less
    • Start date changed from estimate of Apr 2018 to Apr 9, 2018
  26. Trial status: Not Yet Recruiting to Enrolling by Invitation Start date: Jan 2018 to Apr 2018 · Site contacts updated at 2 of 2 sitesv2 Show 2 more changesShow less
    • Start date: Jan 2018 to Apr 2018
    • Site contacts updated at 2 of 2 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Trial Details
NCT Number NCT03391778
Lead Sponsor USWM CT, LLC
Conditions Neoplasms
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov